SAN DIEGO, Dec. 3, 2020 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S.
Department of Veterans Affairs (VA) has awarded the Company a
contract for the purchase of Phexxi® (lactic acid, citric acid and
potassium bitartrate) for a five-year period beginning
December 15, 2020.
Saundra Pelletier, CEO of Evofem
Biosciences, said, "This award is an important milestone in our
ongoing effort to create the broadest access to Phexxi for all
patients. We have achieved coverage for 55% of commercial
lives in the U.S., including nearly 8 million lives at zero copay,
and are very pleased to expand into government programs. We
look forward to providing Phexxi to the women who are a part of
this program, which includes VA, Tricare, Department of Defense,
Coast Guard and Indian Health Services and under which
approximately 12 million lives will have access to
Phexxi."
This award was recently listed on the U.S. government's SAM
website.
About the Department of Veterans Affairs Federal Supply
Schedule (VA FSS)
Under delegated authority by GSA, the VA
manages multiple award contracts for medical equipment, supply,
pharmaceutical, and service Schedule programs. With over
$14 billion in sales, the VA FSS
Service supports the healthcare requirements of the VA and other
federal government agencies by providing Federal customers with
access to over 1 million state-of-the-art commercial products and
services.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is a commercial-stage biopharmaceutical company
committed to developing and commercializing innovative products to
address unmet needs in women's sexual and reproductive health,
including hormone-free, woman-controlled contraception and
protection from certain sexually transmitted infections (STIs). The
Company's first commercial product, Phexxi® (lactic acid, citric
acid and potassium bitartrate), is the first and only hormone-free,
prescription vaginal gel approved in the United
States for the prevention of pregnancy. The Company is
evaluating EVO100 in a Phase 3 clinical
trial, 'EVOGUARD,' for the prevention of urogenital
Chlamydia trachomatis and Neisseria
gonorrhoeae infection in women. For more information,
please visit www.evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences,
Inc.
Forward-Looking Statements
This press release includes
"forward-looking statements," within the meaning of the safe harbor
for forward-looking statements provided by Section 21E of the
Securities Exchange Act of 1934, as amended; and the Private
Securities Litigation Reform Act of 1995, including, without
limitation, statements related to the U.S. Department of Veterans
Affairs contract award. Various factors could cause actual results
to differ materially from those discussed or implied in the
forward-looking statements, and you are cautioned not to place
undue reliance on these forward-looking statements, which are
current only as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties.
Important factors that could cause actual results to differ
materially from those discussed or implied in the forward-looking
statements, or that could impair the value of Evofem Biosciences'
assets and business, are disclosed in Evofem's SEC filings,
including its Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the SEC
on March 12, 2020, its Current Report
on Form 8-K filed with the SEC on June 2,
2020, and its Quarterly Report on Form 10-Q for the quarter
ended September 30, 2020 filed with
the SEC on November 9, 2020. All
forward-looking statements are expressly qualified in their
entirety by such factors. Evofem does not undertake any duty to
update any forward-looking statement except as required by law.
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
Media Contact
Ellen
Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490-3248
View original content to download
multimedia:http://www.prnewswire.com/news-releases/the-us-department-of-veterans-affairs-awards-contract-to-evofem-biosciences-for-phexxi-301185490.html
SOURCE Evofem Biosciences, Inc.